Monobenzone Protocol for Extensive Vitiligo Depigmentation

Patient Selection Criteria

The British Journal of Dermatology recommends monobenzone therapy for adults with disseminated non-segmental vitiligo affecting more than 50% of body surface area who cannot or choose not to pursue repigmentation and who fully accept the permanence of never tanning again 1, 2
Adults with extensive depigmentation of cosmetically sensitive areas, such as the face and hands, are eligible for monobenzone therapy, as per the British Journal of Dermatology guidelines 1, 2, 3
The British Journal of Dermatology suggests that patients must understand and accept the permanent, irreversible nature of complete depigmentation before initiating monobenzone therapy 1, 4
For patients with darker skin types, the British Journal of Dermatology recommends thoroughly discussing and understanding the cultural implications of complete depigmentation 1, 3

The British Journal of Dermatology recommends applying monobenzone to treatment sites, usually limited to exposed areas, such as the face, hands, and forearms, when depigmentation is extensive in these cosmetically sensitive regions 1, 3
The onset of depigmentation occurs within 4-12 months of consistent monobenzone application, as reported by the British Journal of Dermatology 1, 5, 6

The British Journal of Dermatology suggests documenting baseline with serial photographs before treatment initiation and monitoring every 2-3 months with repeat photography to objectively document depigmentation progress, as recommended by the British Journal of Dermatology and Praxis Medical Insights 7
The British Journal of Dermatology recommends watching for local irritation, contact dermatitis, and rarely ochronosis as potential side effects of monobenzone therapy 1, 3, 6

Approximately 36% of patients experience recurrence of pigmentation after 2-36 months, requiring retreatment, as reported by the British Journal of Dermatology 1, 5, 6
Mild burning, itching, and contact dermatitis are common side effects of monobenzone therapy, according to the British Journal of Dermatology 1, 3, 6
Depigmentation is intended to be permanent, and patients will permanently lose the ability to tan, as stated by the British Journal of Dermatology 1, 4
Theoretical concerns about carcinogenicity of hydroquinone derivatives have led to an EU ban from cosmetics in 2001, as noted by the British Journal of Dermatology 1, 6

4-methoxyphenol (4MP) achieves a 69% complete depigmentation rate with a similar 4-12 month onset but also carries a risk of repigmentation, as reported by the British Journal of Dermatology 1, 5, 6
Q-switched ruby laser (QSRL) produces faster depigmentation with a 69% success rate and apparently fewer side effects, though limited evidence exists, according to the British Journal of Dermatology 1, 5, 3

The British Journal of Dermatology recommends ensuring comprehensive patient education on the permanence of depigmentation and the possibility of repigmentation, which may require retreatment 1, 5
Lifelong rigorous sun protection is mandatory after complete depigmentation, as emphasized by the British Journal of Dermatology 4